Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ElexoPharm Appoints Dr. Chris J. van Koppen as Head of Research

Published: Monday, April 16, 2012
Last Updated: Monday, April 16, 2012
Bookmark and Share
Dr. Koppen will lead ElexoPharm’s preclinical drug discovery projects.

ElexoPharm GmbH has announced the appointment of Dr. Chris J. van Koppen as Head of Research.

He will lead the preclinical drug discovery projects of ElexoPharm and will build further alliances with larger pharmaceutical companies.

Dr. van Koppen holds a Ph.D. in Pharmacology and brings extensive industry experience in drug discovery.

Before joining ElexoPharm in January 2012, he served as Leader of four lead optimization projects at Merck Sharp & Dohme, The Netherlands.

He was responsible for delivery of candidate drugs for preclinical development in endocrinological diseases.

Dr. van Koppen was also strongly involved in assay development, HTS, lead finding and proof-of-concept projects.

Before working at MSD, Dr. van Koppen was independent group leader at the Universitätsklinikum Essen and received his Habilitation in Pharmacology and Toxicology.

He has published almost 70 peer-reviewed research papers, including publications in high IF journals (J Biol Chem, Endocrinology, J Clin Endocrinol Metab, PNAS, Mol Pharmacol, Br J Pharmacol, Thorax, Pharmacol Ther, and EMBO Journal).

Axel Koch, Managing Director of ElexoPharm, said: “We are delighted to have such an experienced scientist as Head of Research. His expertise in successfully leading preclinical drug discovery projects will strongly advance our innovative portfolio.”

Dr. van Koppen adds: “I am thrilled to work in the dynamic team of ElexoPharm on highly innovative projects to design and develop drugs for the treatment of endocrinological, cardiovascular and neoplastic diseases.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ElexoPharm GmbH Receives ETB Grant
EuroTransBio grant of €1.5 million for tumor vessel targeting program ('Small Mol Act').
Thursday, October 18, 2012
ElexoPharm Appoints Dr. Chris J. van Koppen as Head of Research
Dr. Koppen will lead the preclinical drug discovery projects of ElexoPharm and will build further alliances with larger pharmaceutical companies.
Monday, April 16, 2012
Scientific News
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
New Diabetes Drug has Unexpected Side Effect
A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Cannabis May Be Used to Treat Fractures
TAU researcher finds non-psychotropic compound in marijuana can help heal bone fissures.
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!